Latest Blogs

May 28, 2020
ASCO20 Virtual is about to begin, and the challenge is finding a way to interact and engage with presenters and other experts in a way we have never done before, writes Dr. Lidia Schapira.
May 27, 2020
The power of touch in this time of physical distancing is top of mind for young adults trying to date, older couples in high-risk groups, and health care professionals who miss the empathy communicated in a handshake or a hug.
May 26, 2020
Stacey Tinianov and I discuss the language of cancer, respecting an individual's context, and empowering patients to be engaged in their care.
May 26, 2020
Dr. Ray Page and I discuss the important role that drug repository programs can play in helping our patients afford their treatment while reducing the financial toll on the cancer care delivery system.
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a Professor Emeritus at the University of Colorado Cancer Center. He previously served as Chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Apr 01, 2020
The TMPRSS2 protein has a role in both COVID-19 and in prostate cancer, suggesting intriguing avenues of inquiry for researchers engaged in the fight against COVID-19.
Sep 09, 2019
A recent study on the risk of Alzheimer's disease or dementia following the use of ADT was disturbing to me on two levels.
Jul 02, 2019
Regardless of prognosis, we all must live with the reality that time is fleeting, and none of us have unlimited tomorrows.
Aug 31, 2018
Some reflections on John McCain, mortality, Hamilton, and the story you leave behind. 
Dec 21, 2016
I cannot count the number of times I have thought to myself, “If it were not for the PSA, you would no doubt be out there playing golf, skiing, biking, taking a grandchild to the park, or just enjoying life.” Living from one PSA to the next is a bad way to mark the passing of time.
Aug 08, 2016
For prostate cancer, there are both challenges and some early positive results from immunotherapy trials that remain intriguing. One of the key challenges is identifying those patients who will benefit from the treatment.

Pages